FDA — authorised 8 September 2023
- Application: NDA217159
- Marketing authorisation holder: AYRMID PHARMA
- Local brand name: APHEXDA
- Indication: POWDER — SUBCUTANEOUS
- Status: approved
🇺🇸 Aphexda in United States
FDA authorised Aphexda on 8 September 2023
Marketing authorisations
FDA
- Marketing authorisation holder: AYRMID PHARMA
- Status: approved
Aphexda in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Aphexda approved in United States?
Yes. FDA authorised it on 8 September 2023; FDA has authorised it.
Who is the marketing authorisation holder for Aphexda in United States?
AYRMID PHARMA holds the US marketing authorisation.